[1] |
Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA):a double-blind, randomised controlled trial. Lancet, 2017; 391, 31-40. http://www.ncbi.nlm.nih.gov/pubmed/29103656 |
[2] |
Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 2007; 356, 1503-16. doi: 10.1056/NEJMoa070829 |
[3] |
Scirica BM, Sabatine MS, Jarolim P, et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes:observations from the MERLIN-TIMI 36 trial. Eur Heart J, 2011; 32, 697-705. doi: 10.1093/eurheartj/ehq468 |
[4] |
Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation, 2004; 110, 3206-12. doi: 10.1161/01.CIR.0000147611.92021.2B |
[5] |
Windhausen F, Hirsch A, Sanders GT, et al. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T:an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J, 2007; 153, 485-92. doi: 10.1016/j.ahj.2006.12.012 |
[6] |
James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease:a Global Utilization of Strategies To Open occluded arteries (GUSTO)-Ⅳ substudy. Circulation, 2003; 108, 275-81. doi: 10.1161/01.CIR.0000079170.10579.DC |
[7] |
de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med, 2001; 345, 1014-21. doi: 10.1056/NEJMoa011053 |
[8] |
Kurtul A, Yarlioglues M, Murat SN, et al. N-Terminal Pro-Brain Natriuretic Peptide Level is Associated With Severity and Complexity of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome. Clin Appl Thromb Hemost, 2016; 22, 69-76. doi: 10.1177/1076029614541954 |
[9] |
Kurtul A, Duran M, Yarlioglues M, et al. Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Clin Cardiol, 2014; 37, 485-92. doi: 10.1002/clc.2014.37.issue-8 |
[10] |
Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med, 2005; 352, 666-75. doi: 10.1056/NEJMoa042330 |
[11] |
Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA, 2007; 297, 169-76. doi: 10.1001/jama.297.2.169 |
[12] |
Ndrepepa G, Braun S, Niemoller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation, 2005; 112, 2102-7. doi: 10.1161/CIRCULATIONAHA.105.550715 |
[13] |
Dai DF, Hwang JJ, Lin JL, et al. Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs. angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease. Circ J, 2008; 72, 1316-23. doi: 10.1253/circj.72.1316 |
[14] |
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 2013; 34, 2949-3003. doi: 10.1093/eurheartj/eht296 |
[15] |
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials:a case for standardized definitions. Circulation, 2007; 115, 2344-51. doi: 10.1161/CIRCULATIONAHA.106.685313 |
[16] |
Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol, 2012; 60, 1581-98. doi: 10.1016/j.jacc.2012.08.001 |
[17] |
Bonaa KH, Mannsverk J, Wiseth R, et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med, 2016; 375, 1242-52. doi: 10.1056/NEJMoa1607991 |
[18] |
Mishra RK, Beatty AL, Jaganath R, et al. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease:the Heart and Soul Study. J Am Heart Assoc, 2014; 3, e000907. http://europepmc.org/abstract/MED/25053234 |
[19] |
Niccoli G, Conte M, Marchitti S, et al. NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. Cardiovasc Revasc Med, 2016; 17, 162-8. doi: 10.1016/j.carrev.2016.02.012 |
[20] |
van Kimmenade RR, Pinto YM, Januzzi JL Jr. Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol, 2008; 101, 39-42. doi: 10.1016/j.amjcard.2007.11.018 |
[21] |
Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides:results from the Dallas Heart Study. Circulation, 2005; 112, 2163-8. doi: 10.1161/CIRCULATIONAHA.105.555573 |
[22] |
Wu N, Ma F, Guo Y, et al. Association of N-terminal pro-brain natriuretic peptide with the severity of coronary artery disease in patients with normal left ventricular ejection fraction. Chin Med J, 2014; 127, 627-32. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhcmj201404007 |
[23] |
Hama N, Itoh H, Shirakami G, et al. Rapid Ventricular Induction of Brain Natriuretic Peptide Gene Expression in Experimental Acute Myocardial Infarction. Circulation, 1995; 92, 1558-64. doi: 10.1161/01.CIR.92.6.1558 |
[24] |
Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J, 2003; 17, 1105-7. doi: 10.1096/fj.02-0796fje |
[25] |
Bibbins-Domingo K, Ansari M, Schiller NB, et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease:data from the Heart and Soul study. Circulation, 2003; 108, 2987-92. doi: 10.1161/01.CIR.0000103681.04726.9C |
[26] |
D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther, 2004; 101, 113-29. doi: 10.1016/j.pharmthera.2003.11.001 |